SOURCE: TheSUBWAY.com

June 02, 2006 09:08 ET

TheSUBWAY.com Posts Stock Pick List: Revolutionizing the Approach to the Treatment of Disease!

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Peter Antipatis of Capital Research Group Inc.

WESTON, FL -- (MARKET WIRE) -- June 2, 2006 -- TheSUBWAY.com names the following stocks to its Stock Pick List: Stem Cell Innovations, Inc. (OTCBB: SCLL), Generex Biotechnology Corporation (NASDAQ: GNBT), Cell Therapeutics, Inc. (NASDAQ: CTIC), Ciena Corporation (NASDAQ: CIEN).

Stem Cell Innovations (OTCBB: SCLL) just announced that Lucio A. Noto has joined its Board of Directors. SCI is a cell biology company based in Texas, with European headquarters in Leiden, Netherlands, capable of creating many types of human stem cells, including nerve, heart and liver, from pluripotent germ cells. SCI is positioned to become a leading provider of toxicology testing and discovery systems for the pharmaceutical, chemical and nutraceutical industries around the world.

Mr. Noto is Managing Partner of the private energy investment company, Midstream Partners, LLC, and he is currently a director on the Boards of IBM, Altria Group, Inc. UAG Inc., Commercial International Bank of Egypt, and Shinsei Bank. He was Chairman and Chief Executive Officer of Mobil Corp. until its merger with Exxon in 1999, when he became Vice Chairman of Exxon Mobil Corporation.

Other stocks highlighted include Generex Biotechnology Corporation (NASDAQ: GNBT): Stock Pick List, down 1% on 2 million shares, Cell Therapeutics, Inc. (NASDAQ: CTIC): Stock Pick List, up 8% on 2 million shares, Ciena Corporation (NASDAQ: CIEN): Stock Pick List, up 4% on 45 million shares.

"Stocks have been hard-pressed to pick a direction in trading lately, going on a tear for a few days, only to see those gains wane in the next several sessions. The Dow Jones Industrial Average is, in fact, just now beginning to break out in the new year, still hovering slightly above the level it was at when the Federal Reserve began raising rates a year ago." More is available at: http://www.thesubway.com.

TheSUBWAY.com's Daily Stock Updates:

TheSUBWAY.com, a leader in corporate communications and finance, highlights stocks that are in the news, have traded high volume, or experienced a large change in price in recent sessions. The aforementioned commentary is not meant to be indicative of a "long term" view of any of the companies listed. For more go to http://www.thesubway.com.

All material herein was prepared by Capital Research Group, Inc. (CRG) based upon information believed to be reliable. The information contained herein is not guaranteed by CRG to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. CRG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.thesubway.com or mentioned herein. CRG has been compensated by third party shareholders or with cash from the company on behalf of one or more of the companies mentioned in this opinion. CRG has been compensated fifty thousand dollars for SCLL. CRG intends to sell its shares. CRG has sold approximately zero SCLL shares to date. CRG may sell its shares for less than the target price given in this opinion. In addition to any compensation mentioned above, additional compensation can be equal to ten percent of any newly issued or registered securities of the profiled companies. CRG's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. CRG will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

Contact Information